A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma

This study is testing a new drug called KC1036 in teenagers aged 12–17 with Ewing sarcoma — a type of bone and soft tissue cancer — that is advanced, has spread, or has failed standard treatments. **You may be eligible if...** - You are between 12 and 17 years old - You have a confirmed diagnosis of Ewing sarcoma - Your cancer is advanced, has spread, or has not responded to standard treatment options - You weigh at least 30 kg (about 66 pounds) - You are in reasonable general health (performance score of 60% or higher) - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have a primary brain tumor or brain metastases - You have had another cancer in the past 5 years - You have had prior treatment with a VEGFR-targeted small molecule drug - You have significant heart, gut, or brain blood vessel problems - You are currently in another therapeutic clinical trial - You are pregnant (for female patients who have started menstruating) Talk to your doctor to see if this trial is right for you.